Management

The AntibioTx team and advisors account for more than 20 drug approvals generating annual revenues in excess of 5 B USD.

 

Dr. Rasmus Toft-Kehler, Chief Executive Officer

Rasmus Toft-Kehler is the CEO of AntibioTx and a co-founder and board member of multiple biotech companies. Prior to entering biotech, Rasmus worked with M&A (Goldman Sachs and Gudme Raaschou), management consulting (Booz Allen Hamilton), and as a board member of a family-owned enterprise until it was successfully sold in 2005.

Rasmus holds a business degree from New York University and Copenhagen Business School and an executive degree from Harvard Business School. Rasmus is the inventor of 5+ patents and has completed a quantitative Ph.D on serial entrepreneurship. His research has been published in leading scientific and entrepreneurship journals such as Nature Reviews Microbiology and the Journal of Business Venturing.

In 2007, Rasmus led a team of four inexperienced sailors to successfully cross the Pacific Ocean.

 

Dr. Morten Sommer, Chief Scientific Officer

Morten Sommer is the co-founder of several biotech companies working within fields of drug development, industrial biotechnology and microbiome research.

Morten is also a Professor and Scientific Director at the Technical University of Denmark with a lab of 20+ Ph.D's and Post docs working primarily in the field of antibiotic resistance and the human microbiome. Morten is the inventor on 20+ issued patents, patent applications and author of scientific papers in journals such as Science, Cell and Nature.

Dr. Sommer holds a Ph.D. in Biophysics from Harvard University from the laboratory of Professor George Church. Dr. Sommer was named Top 10 under 40 on Genetic Engineering and Biotechnology News list of Biopharma Research and Business executives..

 

Dr. Philippe Prokocimer, Chief Medical Officer

Dr. Philippe Prokocimer, M.D. is the Chief Medical Officer of AntibioTx. Dr. Prokocimer was Officer of Trius Therapeutics from July 2007 until its acquisition by Cubist in 2014. At Cubist, Dr. Prokocimer became Senior Vice President of Clinical Development until the acquisition by Merck in January 2015. At Merck, he became Associate Vice President of Clinical Development, Head of San Diego site.

Dr. Prokocimer has been developing anti-infective drugs for 30 years and has been involved with successful approval of 6 New Drug Applications including 5 antibiotics: Doripenem (Doribax®), Quinupristin/dalfopristin (Synercid®), Sparfloxacin (Zagam®), Clarithromycin (Biaxin®) and Tedizolid Phosphate (Sivextros®). Dr. Prokocimer received an M.D. degree from the School of Medicine in Paris, France and a Post-Doctoral Research Fellowship from Stanford University.

 

Morten Boesen, Chief Financial Officer

Morten Boesen holds a M.Sc. in Finance and Accounting from Copenhagen Business School including studies at New York University’s Stern School of Business and Tsinghua University’s School of Economics and Management.

Since 2011 he has worked with EQT, the largest private equity fund in the Nordics, first as an investment manager and subsequently as an executive director in EQT-owned retail company Flying Tiger Copenhagen, where he held responsibility for strategy, business development as well as global commercial and supply chain operations. Prior to that, Mr. Boesen worked as a management consultant with McKinsey & Company, in the M&A advisory of Nordea Bank and in the finance department of Novozymes, the world leader in industrial biotech.

 

Dr. Kurt Jarnagin, VP of Immunology

Kurt Jarnagin, Ph.D. is the VP of Immunology at AntibioTx. Formerly, he was VP of Biological Research at Anacor Pharmaceuticals, where he was responsible for leading biology research in anti-infection and anti-inflammation. Dr. Jarnagin’s experiences included leadership of teams and the conduct of studies in support of Phase 1, 2, 3 & 4.

These studies lead to approval of Eucrisa, a new treatment for atopic dermatitis, and Kerydin, for onychomycosis. Anacor was acquired by Pfizer in 2016 based on the therapeutic benefits of Eucrisa. He was also responsible for conception, preparation, award and PI direction of non-dilutive grants. Dr. Jarnagin has led drug discovery research, target identification, screening and lead optimization programs, in the areas of pharmacology, toxicology and immunology for Iconix, Syntex, and Roche.

He has a Ph.D. in Biochemistry/Minor Chemistry & Pharmacology from University of Wisconsin and did Post-Doctoral studies at UCSF. Dr. Jarnagin has published 58 papers has 11 granted patents.

 

Dr. Lutz Wevelsiep, VP of Regulatory Affairs

Dr. Lutz Wevelsiep, Ph.D. is the Vice President of Regulatory Affairs in AntibioTx and has more than 25 years’ experience in international Regulatory Affairs across Europe and the US within multinational and start-up companies. His experience includes EU decentralized and centralized procedures, product development from Phase I through to marketing authorization as well as particular expertise in anti-infectives. He has prepared and managed various health authority interactions with FDA, EMA and EU national agencies.

Lutz has spent 16 years as Head of Global Regulatory Affairs at Basilea Pharmaceutica. His track record includes successful completion of the European marketing authorization applications for Isavuconazole (Cresmba®), Ceftobiprole (Zevtera®) and Alitretinoin (Toctino®). Lutz holds a Ph.D. and Postdoc in chemistry from the Max-Planck Institute in Germany.

 

Morten Just, VP of Drug Development

Morten Just Petersen has prior experience from multiple drug development projects and has been involved with all stage of development with particular emphasis on regulatory interactions, clinical study design, CMC and execution.

Morten was the COO and later CEO of Astion Pharma A/S. During his time with the company he was in charge of bringing a topical product from the conceptual stage through development and registration before successfully selling the company through a cross-border transaction in 2015.

In 1996 Morten completed an M. Sc. in Chemistry from the University of Copenhagen and subsequently did a post-graduate MBA with emphasis on drug development from the University of Copenhagen.

 

Mads Jellingsø, Head of Commercialization

Mads Jellingsø has broad Market Access experience from Novo Nordisk A/S where he was part of building new functions for Real World Evidence generation and for Innovative Contracting. In these teams Mads was driving Novo Nordisk’s global efforts to initiate partnerships with payers and providers around evidence generation, and developing new financial and outcomes-based approaches to secure access for products in hemophilia, diabetes and obesity.

Mads holds a M.Sc. in Economics from University of Copenhagen, and prior to specializing in Market Access, he has worked with off-shoring and legal affairs in Novo Nordisk and also has experience from management consulting (McKinsey & Company) and banking (Nordea Markets).

 

Dr. Jan Trofast, VP of Patent Strategy

Jan Trofast is the co-inventor of Symbicort (annual >4 Billion USD) and the strategist behind a highly successful patent portfolio of 25+ patents protecting Symbicort and related products. Symbicort is expected to become AstraZeneca’s best selling drug - despite core patent expiration.

Jan Trofast has more than 30 years of experience from AstraZeneca including a number of years with evaluation of internal and external projects.

Jan Trofast obtained a Ph.D. in Organic Chemistry in 1978 and is the author of a significant scientific literature including several publications related to Jacob Berzelius. For his contributions he has been rewarded the Berzelius medal in gold by the Royal Swedish Academy of Sciences in 2001 and the Swedish Medicinal Chemistry Award by the Swedish Pharmaceutical Society in 2010.

 

 


Learn more